Home Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
 

Keywords :   


Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation

2014-07-02 10:39:34| drugdiscoveryonline Home Page

Agenus Inc. an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, recently announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2)

Tags: shows significant generated reduction

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11Costume
24.11BB S604ULS
24.1133
24.11 ElectronicAudioExperimentsDude Incedible
24.11 TC101 5IP 6 NS.NEO 950GH S
24.11
24.11
24.11
More »